Robert J. Kreitman, MD, on Hairy Cell Leukemia: Results From an International Study
2018 ASCO Annual Meeting
Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).
Howard S. Hochster, MD, of Rutgers-Cancer Institute of New Jersey, discusses study findings on irinotecan and cetuximab vs irinotecan, cetuximab, and ramucirumab as second-line therapy of advanced colorectal cancer following oxaliplatin and bevacizumab-based therapy (Abstract 3504).
Danh Pham, MD, of the James Graham Brown Cancer Center, University of Louisville, discusses his findings using a registry on the low rates of screening with low-dose computed tomography, despite its potential to prevent thousands of lung cancer deaths each year (Abstract 6504).
Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses phase II study findings on polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (Abstract 7507).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss the implications of this study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).
Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, discusses phase III findings on pembrolizumab vs platinum-based chemotherapy as first-line treatment for advanced/metastatic non–small cell lung cancer with a PD-L1 tumor proportion score ≥ to 1% (Abstract LBA4).